78964-16-6

Basic information

• Product Name: 2,3:5,6-DI-O-ISOPROPYLIDENE-D-MANNOFURANOSE)
• Synonyms: Furo[3,4-d]-1,3-dioxole,b-D-mannofuranose deriv.
• CAS NO: 78964-16-6
• Molecular Formula: C₁₂H₂₀O₆
• Molecular Weight: 260.29
• Mol File: 78964-16-6.mol
• Article Data: 59

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,3:5,6-DI-O-ISOPROPYLIDENE-D-MANNOFURANOSE)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3:5,6-DI-O-ISOPROPYLIDENE-D-MANNOFURANOSE)(78964-16-6)
• EPA Substance Registry System: 2,3:5,6-DI-O-ISOPROPYLIDENE-D-MANNOFURANOSE)(78964-16-6)

Safety Data

• Hazardous Substances Data: 78964-16-6(Hazardous Substances Data)

Upstream product

• 3458-28-4 D-Mannose 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 
• 530-26-7 D-Mannose 
• 1128-23-0 L-gulono-1,4-lactone 
• 50-81-7 ascorbic acid 
• 7306-64-1 2,3:5,6-di-O-isopropylidene-L-gulonolactone 
• 49561-21-9 (3aR,6S,6aR)-6-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-4(3aH)-one 
• 75-52-5 nitromethane 
• 5328-37-0 L-arabinose 
• 116-11-0 2-Methoxypropene 
• 582-52-5 1,2:5,6-Di-O-isopropylidene-α-D-glucofuranose 

Downstream Products

• 6160-67-4 (3aS,4R,6R,6aS)-4-chloro-6-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole 
• 6160-67-4 (3aS,6R,6aS)-4-Chloro-6-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 7306-64-1 2,3,5,6-di-O-isopropylidene-D-mannono-1,4-lactone 
• 869354-98-3 benzyl 2,3: 5,6-di-O-isopropylidene-D-mannofuranoside 
• 14440-57-4 1-O-acetyl-2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 
• 181173-63-7 (3aS,4R,6R,6aS)-4-(3-Benzyloxy-2-tetradecyloxy-propoxy)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 181173-64-8 (3aS,4R,6R,6aS)-4-(3-Benzyloxy-2-hexadecyloxy-propoxy)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 181173-66-0 (3aS,4S,6R,6aS)-4-(3-Benzyloxy-2-hexadecyloxy-propoxy)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 181173-65-9 (3aS,4R,6R,6aS)-4-(3-Benzyloxy-2-octadecyloxy-propoxy)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 181173-67-1 (3aS,4S,6R,6aS)-4-(3-Benzyloxy-2-octadecyloxy-propoxy)-6-((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 164665-76-3 4-methoxybenzyl 2,3,5,6-di-O-isopropylidene-α-D-mannofuranoside 
• 20689-02-5 benzyl 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 

Relevant articles and documents

Straightforward synthesis of protected 2-hydroxyglycals by chlorination-dehydrochlorination of carbohydrate hemiacetals

A straightforward and scalable method for the synthesis of protected 2-hydroxyglycals is described. The approach is based on the chlorination of carbohydrate-derived hemiacetals, followed by an elimination reaction to establish the glycal moiety. 1,2-dehy

Discovery and Structure-Activity Relationships of Novel Template, Truncated 1′-Homologated Adenosine Derivatives as Pure Dual PPARγ/δModulators

Following our report that A3 adenosine receptor (AR) antagonist 1 exhibited a polypharmacological profile as a dual modulator of peroxisome proliferator-activated receptor (PPAR)γ/δ, we discovered a new template, 1′-homologated adenosine analogues 4a-4t, as dual PPARγ/δmodulators without AR binding. Removal of binding affinity to A3AR was achieved by 1′-homologation, and PPARγ/δdual modulation was derived from the structural similarity between the target nucleosides and PPAR modulator drug, rosiglitazone. All the final nucleosides were devoid of AR-binding affinity and exhibited high binding affinities to PPARγ/δbut lacked PPARα binding. 2-Cl derivatives exhibited dual receptor-binding affinity to PPARγ/δ, which was absent for the corresponding 2-H derivatives. 2-Propynyl substitution prevented PPARδ-binding affinity but preserved PPARγaffinity, indicating that the C2 position defines a pharmacophore for selective PPARγligand designs. PPARγ/δdual modulators functioning as both PPARγpartial agonists and PPARδantagonists promoted adiponectin production, suggesting their therapeutic potential against hypoadiponectinemia-associated cancer and metabolic diseases.

PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING GLAUCOMA, CONTAINING ADENOSINE DERIVATIVE

A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided. The pharmaceutical composition for preventing or treating eye diseases comprises the compound repre